These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 35603152)

  • 1. Corrigendum: Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis.
    Zhu M; Zeng Q; Fan T; Lei Y; Wang F; Zheng S; Wang X; Zeng H; Tan F; Sun N; Xue Q; He J
    Front Immunol; 2022; 13():909105. PubMed ID: 35603152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance and inflammatory landscapes of a novel recurrence-associated immune signature in early-stage lung adenocarcinoma.
    Zhang C; Zhang Z; Zhang G; Zhang Z; Luo Y; Wang F; Wang S; Che Y; Zeng Q; Sun N; He J
    Cancer Lett; 2020 Jun; 479():31-41. PubMed ID: 32201203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
    Wu P; Zheng Y; Wang Y; Wang Y; Liang N
    J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid metabolism gene-wide profile and survival signature of lung adenocarcinoma.
    Li J; Li Q; Su Z; Sun Q; Zhao Y; Feng T; Jiang J; Zhang F; Ma H
    Lipids Health Dis; 2020 Oct; 19(1):222. PubMed ID: 33050938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Immune-Related lncRNA Expression Profile to Improve Prognosis Prediction for Lung Adenocarcinoma: From Bioinformatics to Clinical Word.
    Zhang B; Wang R; Li K; Peng Z; Liu D; Zhang Y; Zhou L
    Front Oncol; 2021; 11():671341. PubMed ID: 33968781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A B7-CD28 family based signature demonstrates significantly different prognoses and tumor immune landscapes in lung adenocarcinoma.
    Zheng S; Luo X; Dong C; Zheng D; Xie J; Zhuge L; Sun Y; Chen H
    Int J Cancer; 2018 Nov; 143(10):2592-2601. PubMed ID: 30152019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and Validation of Lactate Metabolism-Related lncRNA Signature as a Prognostic Model for Lung Adenocarcinoma.
    Mai S; Liang L; Mai G; Liu X; Diao D; Cai R; Liu L
    Front Endocrinol (Lausanne); 2022; 13():829175. PubMed ID: 35422758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel seven-long non-coding RNA signature predicts survival in early stage lung adenocarcinoma.
    Chen M; Liu B; Xiao J; Yang Y; Zhang Y
    Oncotarget; 2017 Feb; 8(9):14876-14886. PubMed ID: 28122330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinoma.
    Song Q; Shang J; Yang Z; Zhang L; Zhang C; Chen J; Wu X
    J Transl Med; 2019 Mar; 17(1):70. PubMed ID: 30832680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a novel snoRNA expression signature associated with overall survival in patients with lung adenocarcinoma: A comprehensive analysis based on RNA sequencing dataset.
    Zhang L; Xin M; Wang P
    Math Biosci Eng; 2021 Sep; 18(6):7837-7860. PubMed ID: 34814278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comment on 'Clinical significance and inflammatory landscapes of a novel recurrence associated immune signature in early-stage lung adenocarcinoma'.
    Chen D; Wu X; Chen Y; Chen C
    Cancer Lett; 2020 Dec; 494():17. PubMed ID: 32781014
    [No Abstract]   [Full Text] [Related]  

  • 12. Identification of a novel gene expression signature associated with overall survival in patients with lung adenocarcinoma: A comprehensive analysis based on TCGA and GEO databases.
    Zhao J; Guo C; Ma Z; Liu H; Yang C; Li S
    Lung Cancer; 2020 Nov; 149():90-96. PubMed ID: 33002836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to comment on 'Clinical significance and inflammatory landscapes of a novel recurrence-associated immune signature in early-stage lung adenocarcinoma'.
    Sun N; Zhang C; He J
    Cancer Lett; 2020 Dec; 494():5-6. PubMed ID: 32763273
    [No Abstract]   [Full Text] [Related]  

  • 14. Comprehensive molecular analyses of a TNF family-based signature with regard to prognosis, immune features, and biomarkers for immunotherapy in lung adenocarcinoma.
    Zhang C; Zhang G; Sun N; Zhang Z; Zhang Z; Luo Y; Che Y; Xue Q; He J
    EBioMedicine; 2020 Sep; 59():102959. PubMed ID: 32853987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corrigendum: NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis.
    Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ
    Front Immunol; 2021; 12():751004. PubMed ID: 34531879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of pyroptosis-related factors in lung adenocarcinoma.
    Lin X; Zhou T; Hu S; Yang L; Yang Z; Pang H; Zhou X; Zhong R; Fang X; Yu Z; Hu K
    J Thorac Dis; 2022 Mar; 14(3):654-667. PubMed ID: 35399245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of an immune-related six-long noncoding RNA signature as a novel prognosis biomarker for adenocarcinoma of lung.
    Miao H; Chen D; Li R; Hu J; Chen Y; Xu C; Wen Z
    Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33324975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Li N; Li Y; Zheng P; Zhan X
    Front Endocrinol (Lausanne); 2021; 12():755805. PubMed ID: 34745015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Seven-Gene Signature with Close Immune Correlation Was Identified for Survival Prediction of Lung Adenocarcinoma.
    Zou X; Hu Z; Huang C; Chang J
    Med Sci Monit; 2020 Jul; 26():e924269. PubMed ID: 32613949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
    Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
    Front Immunol; 2021; 12():693062. PubMed ID: 34497605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.